Insights into Cancer Stem Cells

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Tumor Microenvironment".

Deadline for manuscript submissions: 31 July 2024 | Viewed by 972

Special Issue Editor


E-Mail Website
Guest Editor
Department of Cell and Cancer Biology, College of Medicine and Life Sciences, Health Science Campus, University of Toledo, Toledo, OH 43614, USA
Interests: chemokine receptors; chemotaxis; cap-dependent mRNA translation in cancer; eukaryotic translation initiation factors, eIF4A1, metastasis; breast cancer; pancreatic cancer; precision medicine/targeted therapy; small molecule inhibitors
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Cancer stem cells (CSCs) or cancer stem-like cells (CSLCs) comprise a small percentage of cells (2–5%) in a given tumor type. Despite this fact, they play a vital role in minimal residual disease and subsequent relapse with associated chemoresistance. Cancer stemness has been a challenge in clinical settings to overcome therapy failure. Simultaneous elimination of CSCs or CSLCs and bulk tumor cells is critical to win the chemotherapy battle.

For this Special Issue of Cancers, we welcome original research and review articles that provide an overview of the most recent advances and future challenges involving CSCs or CSLCs: (1) novel and vulnerable molecular targets; (2) novel autocrine pathways and paracrine mechanisms between CSCs and stromal elements such as immune cells; (3) development of novel therapies including immunotherapies; (4) drug resistance mechanisms; (5) mechanisms by which pluripotency is regulated and maintained; (6) CSC niche; (7) novel and emerging technologies to study cancer stemness; (8) epigenetic influences on CSC/CSCLs.

Dr. Dayanidhi Raman
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

19 pages, 2779 KiB  
Article
Influence of Aldehyde Dehydrogenase Inhibition on Stemness of Endometrial Cancer Stem Cells
by Beatriz Serambeque, Catarina Mestre, Gabriela Correia-Barros, Ricardo Teixo, Carlos Miguel Marto, Ana Cristina Gonçalves, Francisco Caramelo, Isabel Silva, Artur Paiva, Hans C. Beck, Ana Sofia Carvalho, Maria Filomena Botelho, Maria João Carvalho, Rune Matthiesen and Mafalda Laranjo
Cancers 2024, 16(11), 2031; https://doi.org/10.3390/cancers16112031 - 27 May 2024
Viewed by 687
Abstract
Endometrial cancer is one of the most common gynaecological malignancies. Although often diagnosed at an early stage, there is a subset of patients with recurrent and metastatic disease for whom current treatments are not effective. Cancer stem cells (CSCs) play a pivotal role [...] Read more.
Endometrial cancer is one of the most common gynaecological malignancies. Although often diagnosed at an early stage, there is a subset of patients with recurrent and metastatic disease for whom current treatments are not effective. Cancer stem cells (CSCs) play a pivotal role in triggering tumorigenesis, disease progression, recurrence, and metastasis, as high aldehyde dehydrogenase (ALDH) activity is associated with invasiveness and chemotherapy resistance. Therefore, this study aimed to evaluate the effects of ALDH inhibition in endometrial CSCs. ECC-1 and RL95-2 cells were submitted to a sphere-forming protocol to obtain endometrial CSCs. ALDH inhibition was evaluated through ALDH activity and expression, sphere-forming capacity, self-renewal, projection area, and CD133, CD44, CD24, and P53 expression. A mass spectrometry-based proteomic study was performed to determine the proteomic profile of endometrial cancer cells upon N,N-diethylaminobenzaldehyde (DEAB). DEAB reduced ALDH activity and expression, along with a significant decrease in sphere-forming capacity and projection area, with increased CD133 expression. Additionally, DEAB modulated P53 expression. Endometrial cancer cells display a distinct proteomic profile upon DEAB, sharing 75 up-regulated and 30 down-regulated proteins. In conclusion, DEAB inhibits ALDH activity and expression, influencing endometrial CSC phenotype. Furthermore, ALDH18A1, SdhA, and UBAP2L should be explored as novel molecular targets for endometrial cancer. Full article
(This article belongs to the Special Issue Insights into Cancer Stem Cells)
Show Figures

Figure 1

Back to TopTop